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Abstract: With an increasing number of cancer proﬁ  ling studies assaying both transcript mRNA and copy number expression 
levels, a natural question then involves the potential to combine information across the two types of genomic data. In this 
article, we perform a study to assess the nature of association between the two types of data across several experiments. We 
report on several interesting ﬁ  ndings: 1) global correlation between gene expression and copy number is relatively weak 
but consistent across studies; 2) there is strong evidence for a cis-dosage effect of copy number on gene expression; 
3) segmenting the copy number levels helps to improve correlations.
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Introduction
With the explosion of high-throughput technologies for measuring various aspects of molecular activ-
ity, it has become possible to globally monitor the biochemical activities of cells. Much of the applica-
tion of these technologies has been in the area of cancer, one major example of which is transcript 
mRNA microarrays (Schena, 2002). There is now a vast literature on microarray studies done in cancer; 
a simple PubMed search of the phrase “microarray data, cancer” turns up approximately 2400 entries, 
99% of which have been published since 2000.
While there have been many examples of individual molecules, genomic signatures and pathways 
that have been discovered as being dysregulated in cancer through analyses of gene expression data, a 
more promising avenue is arising based on consideration of integrating genomic data sources in order 
to validate previous ﬁ  ndings based on gene expression studies and to decipher higher-order modular 
mechanisms of co-expressed genes enriched in various molecular pathways (Rhodes and Chinnaiyan, 
2005; Segal et al. 2005).
In cancer, chromosomal aberrations occur frequently. Various types of cytogenetic aberrations, 
including segmental ampliﬁ  cation/deletion and unbalanced translocation events, are a major character-
istic of the majority of epithelial tumors. These complex transformations lead to activation of oncogenes 
and inactivation of tumor suppressor genes. There are many examples of genes that undergo ampliﬁ  ca-
tions in cancer, including AKT2 in ovarian cancer, ERRB2 in breast and ovarian cancer, MYCL1 in 
small cell lung cancer, MYCN in neuroblastoma and EGFR in glioma and non-small cell lung cancer; 
a comprehensive account of these and other cancer-related genes can be found in Futreal et al. (2004). 
It has also been shown that many of these changes correlate with clinical factors, such as survival, stage 
and response to treatment. As an example, for metastatic breast cancer patients with the ERBB2 gene 
ampliﬁ  cation, trastuzumab (Herceptin) is a targeted therapy that is available to achieve a better 
prognosis.
There are now studies in which microarray data on both an mRNA transcript level as well as a copy 
number level are being collected. As demonstrated in Virtaneva et al. (2001), a correlation exists between 
copy number and gene expression in cancer. There are other potential advantages to the integration of 
copy number and gene expression data. Ludwig and Weinstein (2005) write that the integration of mRNA 
transcript and copy number information could lead to the identiﬁ  cation of new biomarkers. Similarly, 
Myllykangas and Knuutila (2006) write that integration of copy number and gene expression data can 
potentially be used to “understand the effects of gene regulation and transcription in ampliﬁ  cation 
manifestation.” With the recently funded Cancer Genome Atlas (http://cancergenome.nih.gov), multiple 
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levels of genomic data are being collected on tumor 
samples. This will be a valuable resource to the 
cancer research community. A key question then 
will be how to combine such genomic datasets.
While there are currently few studies in which 
both transcript mRNA and copy number microar-
rays are collected on matched samples, we give 
two examples which have yielded promising 
results. In a study by Garraway et al. (2005), the 
authors examined Affymetrix SNP array data gen-
erated on the celebrated NCI-60 cell line data and 
then sought to ﬁ  nd alterations between tissue-
speciﬁ  c cancers. Based on such differences, they 
then looked for differentially expressed genes in 
the regions that showed overampliﬁ  cation in the 
corresponding cell lines. These analyses implicated 
a new candidate oncogene, MITF. In another study 
using copy number and gene expression study data 
from the NCI 60 cell line dataset, Bussey et al. 
(2006) explored the behavior of 64 candidate 
oncogenes based on correlations between gene 
expression, copy number and compound activity 
score. Based on these correlations, they were able 
to nominate some candidate biomarkers. We term 
studies of this type as being in the area of cancer 
“integromics,’’ where data measuring different 
biochemical activities are measured on the same 
samples. They demonstrate the potential of such 
datasets to better identify candidate biomarkers in 
disease progression and prognosis.
In this study, global associations between gene 
expression and copy number are examined across 
studies of multiple cancer types. This analysis was 
motivated for the following reasons. First, knowing 
the general pattern of correlation structure between 
the two data types allows us to assess the feasibil-
ity of integrative analysis in terms of expected 
(within-sample) signal-to-noise ratio and variabil-
ity of the association between copy number and 
gene expression across samples. Second, it is 
important to know if the correlation between gene 
expression and copy number generalizes across 
different sites of origin. Third, correlation between 
the two types of data may differ by the nature of 
samples. In particular, copy number characteriza-
tion will be distinct depending on whether the study 
is in vivo or in vitro. Much of the results reported 
will be of a descriptive nature. Finally, we will 
explore higher-order correlations using modern 
machine learning methodologies (Efron et al. 
2004) as well as bioinformatic methods for 
segmenting genomic data (Olshen et al. 2004).
Methods
Datasets
Only genomic datasets in which the same samples 
were proﬁ  led on a genomic DNA and transcrip-
tomic basis using two-channel microarray plat-
forms were considered here. Use of the same array 
(probe) designs on both data types avoids having 
to perform inter-platform identiﬁ  cation mapping 
of genes.
We searched the Stanford microarray database 
(http://genome-www5.stanford.edu/), Gene 
Expression Omnibus (http://www.ncbi.nlm.nih.
gov/geo/) and ArrayExpress (http://www.ebi.ac.uk/
arrayexpress/) in November 2006 for such com-
plete datasets. Datasets from the following pub-
lished studies were used: Pollack et al. (2002); 
Hyman et al. (2002); Heidenblad et al. (2005); 
Zhao et al. (2005) and Kim et al. (2006). Here and 
in the sequel, we will refer to these datasets by the 
name of the ﬁ  rst author. There are three things we 
note about the datasets. First, all of the datasets 
except for that from Pollack et al. (2002) are from 
cancer cell lines. Second, the cell lines are from 
different tissues of origin. This will allow us to 
observe tissue-specific phenomena. Third, the 
Hyman et al. (2002) and Pollack et al. (2002) breast 
datasets will allow us to assess concordance of 
copy number/transcript correlations between 
in vivo and in vitro systems.
Data Preprocessing
Missing data were imputed using a k-nearest 
neighbors algorithm with k = 5 (Troyanskaya 
et al. 2001). Then, a variance ﬁ  lter was applied 
to the transcript mRNA and copy number micro-
array datasets separately. The spots with the 
lowest 25% variance across all samples were 
excluded from each dataset. This was done to 
ensure that the correlations calculated in the study 
would not be subject to artefacts arising from 
experimental noise. The ﬁ  nal numbers of genes 




As an initial analysis, we calculated Pearson cor-
relation between the expression level of every gene 
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with its corresponding copy number expression 
proﬁ  le. This is shown in Table 2.
Comparing the median values for correlation 
between transcript mRNA and copy number across 
the ﬁ  ve studies is equivalent to the copy number 
explaining 12%–40% of the variation in gene expres-
sion across the ﬁ  ve studies. Compared to the 12% 
ﬁ  gure given by Pollack et al. (2002), we ﬁ  nd evi-
dence of stronger association in the cell line datasets 
than in the human tissue. In general, we ﬁ  nd weak 
correlation globally between the transcript mRNA 
and copy number expression levels. However, on 
average, we can also say that the correlation distribu-
tion appears fairly consistent across studies, with the 
one exception being the Zhao et al. study, which 
appears to have a greater amount of variability than 
the other studies. This is probably due to the small 
sample size of the study; it has the lowest number of 
samples among the studies.
We next summarized all possible pairwise uni-
variate correlations between gene expression and 
copy number. The results are given in Table 3.The 
correlation between a gene’s expression level and 
corresponding copy number rarely represents the 
largest correlation in terms of magnitude in the data-
set. Table 3 suggests that there tends to be stronger 
correlation between transcript levels and copy num-
ber if we consider genes from the same chromosome; 
however, the increase in the proportion of genes with 
high correlation remains modest. This is a consistent 
ﬁ  nding with the notion of regulation of gene expres-
sion not being a simple relationship. It is also sug-
gestive of a so-called “cis-dosage’’ effect of copy 
number on transcription. We further explored this 
association using more modern data mining 
techniques in the next section.
Higher-order correlation studies
While Table 1 provides a nice summary of the 
univariate correlations, we also explored higher-
order correlation modelling strategies. In particu-
lar, we wished to allow for the effects of copy 
number expression from multiple loci to inﬂ  uence 
the transcription level of a gene.
The approach we tried was Least Angle Regres-
sion (“LARS”) (Efron et al. 2004). It involves ﬁ  tting 
a linear regression model in which the response vari-
able is gene expression and the copy number expres-
sion values from all loci are potential predictors. 
Since the possible number of predictors is much 
greater than the number of samples, it is impossible 
to obtain a unique estimate of the linear regression 
model. The LARS algorithm allows the user to ﬁ  t 
such a model; its estimation procedure involves a 
sequential and iterative ﬁ  tting procedure where only 
m sequential steps are taken. In our case, we take 
m = (number of samples)/2. This implies that a large 
fraction of the regression coefﬁ  cients will be esti-
mated to be exactly zero. Below is a description of 
the LARS procedure:
1.   All coefﬁ  cients are equal to zero at the begin-
ning, ﬁ  nd the predictor most correlated with the 
response, denote as xj1.
2.   With xj1 we ﬁ  nd xj2 which is most correlated 
with the current residual vector.
Table 1. Description of datasets used in the analysis. Dataset column refers to ﬁ  rst author on publication containing 
data.
Dataset  Organ site  In vivo/in vitro  Number of genes  Number of samples
Pollack Breast  In  vivo  4841  36
Hyman Breast  In  vitro  6823  14
Heidenblad Pancreas  In  vitro  8879  16
Zhao Prostate  In  vitro  14824  8
Kim Lung  In  vitro 21066  22
Table 2. Summary statistics for pair wise correlation between copy number and expression.
Dataset  Min  1st Quantile  Median  Mean  3rd Quantile  Max  SD
Pollack  −0.49  −0.02 0.11  0.12 0.26 0.90  0.22
Hyman  −0.83  −0.07 0.14  0.15 0.36 0.99  0.31
Heidenblad  −0.79  −0.04 0.16  0.15 0.34 0.92  0.28
Zhao  −0.95  −0.14 0.19  0.16 0.48 0.99  0.41
Kim  −0.79  0.02 0.22  0.20 0.39 0.94  0.27
Notes: Min refers to minimum; Max refers to maximum. SD is standard deviation.
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3.   Proceed equiangularly between the two predic-
tors until a third covariate xj3 enters the “most 
correlated” set.
4.  Proceed equiangularly between xj1, xj21 and xj3 
until the fourth covariate enters, and so on.
After m steps, we stop. Thus in the ﬁ  nal results 
of the regression, for each response there are only 
m covariates have non-zero estimated coefﬁ  cients. 
Such an approach allows for multiple copy number 
expression values to influence a given gene’s 
mRNA transcript levels.
Given the results of the LARS analyses for each 
gene, we can test for a cis-dosage effect. If such 
an effect exists, then this means that the mRNA 
expression of one gene is more correlated with the 
DNA copy number of genes located on the same 
chromosome than with DNA copy number of genes 
from different chromosomes. We tested for the 
presence of a cis-dosage effect using a Wilcoxon 
test. These results are summarized in Supplemen-
tary Table 1.
We draw several conclusions from the table. 
First, the strength of the cis-dosage effect varies 
across cancer type. For the purposes of interpret-
ing the table, if we assumed that there was no 
cis-dosage effect globally, we still would expect 
approximately one chromosome to show signiﬁ  -
cant evidence of a cis-dosage effect if we are 
testing at a signiﬁ  cance level of 0.05. It is most 
signiﬁ  cant for breast cancer, showing twenty 
signiﬁ  cant chromosomes for the Pollack et al. 
data and 16 significant chromosomes for the 
Hyman et al. (2002) data. However, for the pros-
tate cancer cell line there only exist 9 signiﬁ  cant 
chromosomes. The correlation patterns for cancer 
tumor tissue and cell lines from the Pollack and 
Hyman et al. data, which are both from breast 
cancer, are similar in that both show strong over-
all location effect. In conclusion, based on our 
analysis, the relationship between copy number 
and expression level is appears to be greater than 
captured by simple correlation, and the signiﬁ  -
cance of this relationship varies for different 
cancer types.
The other correlation analysis we performed 
was to take into account that copy number and 
gene expression levels might have spatial correla-
tion. This is accommodated through the use of 
segmentation techniques (Olshen et al. 2004). In 
particular, we repeated the correlation of analysis 
in Table 2 by segmenting both the copy number 
and the gene expression data. Various correlations 
were calculated and are summarized in Table 4. 
This table shows that the single gene copy number-
transcript mRNA correlations improve by incor-
porating segmentation methods into the analysis. 
This also suggests that incorporating the spatial 
correlation in gene expression and copy number 
expression will improve the amount of gene 
expression variation that is explained by copy 
number expression.
Discussion
In this study, we have explored the nature of cor-
relation between transcript mRNA and copy num-
ber for genes across ﬁ  ve cancer proﬁ  ling studies 
in which both types of measurements were col-
lected on the same samples. Three ﬁ  ndings are 
notable from this study:
1.   The global nature of correlation between tran-
script mRNA and copy number is in accor-
dance with what is reported in Pollack et al. 
(2002) and appear to be consistent across 
studies.
2.   There is solid evidence for a cis-dosage effect 
of copy number on transcription.
3.   Segmentation of genomic data leads to better 
correlation, even more than what has been sug-
gested by Pollack et al.
Table 3. Summary of univariate correlation results across ﬁ  ve studies.
Dataset  Number of genes  # genes most correlated  # genes most correlated with genes
    with themselves  from the same chromosome
Pollack  4841  42 (0.90%)  619 (13.21%)
Hyman  6823  28 (0.41%)  648 (9.50%)
Heidenblad  8879  8 (0.09%)  713 (8.03)
Zhao  14284  3 (0.02%)  853 (6.09%)
Kim  21066  79 (0.5%)  2344 (14.0%)
Notes: In this table, the second column refers to the number of genes in which the largest correlation in magnitude with copy number is that 
from the same gene (i.e. the same spot on the microarray). The third column refers to the number of genes whose largest correlation between 
expression and copy number was with a spot that mapped to a gene on the same chromosome.
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The ﬁ  rst result suggests that other phenomena 
might control and hence be able to explain the 
variation in gene expression. Examples include 
histone modiﬁ  cations, mutations in DNA sequence, 
microRNA molecules and protein activity. This 
study outlines that there are still many factors that 
are needed to explain gene expression. With the 
explosion in new technologies, the effects of other 
factors on gene expression could potentially be 
studied. A second and more statistical point is that 
the weak overall correlation suggests that the 
approach authors have taken of focusing on speciﬁ  c 
genes or molecules from “integromic’’ analyses of 
gene expression and copy number data seem to be 
quite reasonable. If there were stronger correlations 
between gene expression and copy number, then 
there would be potential advantage in pooling results 
from spatially contiguous genes; however, this 
approach might not lead to any gains in power, given 
the nature of correlation that we are ﬁ  nding here. 
Of course, if there are sample-speciﬁ  c artefacts, then 
using the correlation coefﬁ  cient across samples 
might lead to erroneous conclusions.
One major limitation of our study is that we are 
not considering clinically heterogeneous samples 
at all, i.e. we treat each study as having samples 
coming from one population. With samples from 
the Cancer Genome Atlas, there will be linked 
clinical information to the genomic data. It might 
be the case that the nature of correlation will 
change depending on certain clinical parameters. 
This was the approach implicitly utilized by Bussey 
et al. (2006) and is potentially powerful for ﬁ  nding 
new biomarkers. How to incorporate clinical infor-
mation into the analysis is an open area of research 
and is currently under investigation.
Much of the results we have reported have been 
based on descriptive measures. A challenging issue 
is how to perform statistical inference. While per-
mutation procedures are quite popular, it is not 
Table 4. Correlations across ﬁ  ve datasets taking segmentation into account.
Hyman  0%  25%  50%  75%  100%  SD  MAD
Both Unsegmented  −0.859  −0.057 0.159 0.373 0.956 0.303  0.246
Expression Segmented  −0.805  −0.025 0.211 0.432 0.974 0.317  0.259
Copynumber Segmented  −0.902  −0.022 0.219 0.453 0.969 0.324  0.267
Both Segmented  −0.734  0.259 0.471 0.652 0.976 0.281  0.224
Heidenblad  0%  25%  50%  75%  100%  SD  MAD
Both Unsegmented  −0.777  −0.051  0.147 0.34 0.949 0.276  0.224
Expression Segmented  −0.746 0.069 0.268 0.463  0.948  0.285  0.229
Copynumber Segmented  −0.804  −0.008 0.196 0.395  0.952 0.288  0.234
Both Segmented  −0.691 0.247 0.464 0.645  0.975  0.288  0.231
Pollack  0%  25%  50%  75%  100%  SD  MAD
Both Unsegmented  −0.547  −0.028 0.106 0.248 0.898 0.208  0.165
Expression Segmented  −0.607  0.082 0.241 0.399 0.947 0.226  0.183
Copynumber Segmented  −0.54  0.005 0.166 0.331 0.914 0.231  0.186
Both Segmented  −0.396 0.327  0.479  0.62 0.971  0.214  0.172
Zhao  0%  25%  50%  75%  100%  SD  MAD
Both Unsegmented  −0.946  −0.127  0.196 0.488 0.989 0.406  0.338
Expression Segmented  −0.939 0.085 0.42 0.675  0.99  0.401  0.331
Copynumber Segmented  −0.968  −0.115 0.227  0.525  0.99  0.418  0.348
Both Segmented  −0.923  0.309  0.623 0.819 0.997 0.383  0.304
Kim  0%  25%  50%  75%  100%  SD  MAD
Both Unsegmented  −0.803 0.051 0.241  0.42 0.972  0.263  0.214
Expression Segmented  −0.726  0.124  0.328 0.522 0.932 0.279  0.228
Copynumber Segmented  −0.722  0.077  0.287 0.479 0.957 0.278  0.228
Both Segmented  −0.644  0.275  0.482 0.675 0.924 0.282  0.228
Notes: SD represents standard deviation; MAD represents mean absolute deviation. Both Unsegmented refers to correlation coefﬁ  cients 
between gene expression and copy number based on the raw expression number value, after taking the preprocessing steps described in 
the paper. Expression Segmented refers to running the algorithm of Olshen et al. (2004) on the gene expression data on individual samples 
and to then calculate the correlation coefﬁ  cients between gene expression and copy number expression. Copynumber Segmented refers 
to running the algorithm of Olshen et al. (2004) on the copy number expression data on individual samples and to then calculate the cor-
relation coefﬁ  cients between gene expression and copy number expression. Both Segmented refers to running the algorithm of Olshen et al. 
(2004) on the copy number and gene expression data on individual samples and to then calculate the correlation coefﬁ  cients between gene 
expression and copy number expression.
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clear what should be permuted. In addition, if one 
wishes to incorporate spatial dependence, then 
clearly a model-based approach is needed.
Finally, this should be viewed as an initial study 
in the area. With the possibility of larger-sized 
datasets emerging in the future, the nature of copy 
number and gene expression will be more reliably 
assessed. By ﬁ  nding consistent patterns across the 
individual datasets, this provides some strength of 
evidence to our study.
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Table S1. Results of the LARS analyses to ﬁ  nd cis-dosage effects of copy number on gene expression. The results are grouped by ﬁ  rst 
study author. Chrm refers to chromosome. Average number of non-zero betas denotes the average number of copy number expression 
measurements from the same chromosome found to have a non-zero effect on gene expression for all genes on the chromosome. Expected 
number of non-zero betas denotes the average number of non-zero betas under the null hypothesis of no-cis dosage effect. P-value is based 
on the Wilcoxon rank-sum test.
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